NASDAQ:CRSPCrispr Therapeutics Stock Price, Forecast & News

Crispr Therapeutics' stock was trading at $43.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRSP stock has increased by 106.7% and is now trading at $89.47. View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crispr Therapeutics.

Crispr Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Crispr Therapeutics.

Crispr Therapeutics AG (NASDAQ:CRSP) released its quarterly earnings data on Tuesday, April, 28th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.05) by $0.10. The firm earned $0.16 million during the quarter, compared to analysts' expectations of $3.04 million. Crispr Therapeutics had a net margin of 15.73% and a return on equity of 6.54%. The firm's quarterly revenue was down 52.1% on a year-over-year basis. During the same period last year, the business posted ($0.93) earnings per share. View Crispr Therapeutics' earnings history.

15 Wall Street analysts have issued twelve-month price objectives for Crispr Therapeutics' stock. Their forecasts range from $31.00 to $105.00. On average, they expect Crispr Therapeutics' stock price to reach $75.81 in the next year. This suggests that the stock has a possible downside of 15.3%. View analysts' price targets for Crispr Therapeutics.

Media coverage about CRSP stock has trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Crispr Therapeutics earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Crispr Therapeutics.

Crispr Therapeutics saw a decrease in short interest in June. As of June 15th, there was short interest totaling 3,890,000 shares, a decrease of 8.9% from the May 31st total of 4,270,000 shares. Based on an average daily volume of 936,900 shares, the days-to-cover ratio is currently 4.2 days. Approximately 8.8% of the shares of the company are short sold. View Crispr Therapeutics' Current Options Chain.

Some companies that are related to Crispr Therapeutics include NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), Neurocrine Biosciences (NBIX), argenx (ARGX), BIO-TECHNE (TECH), Qiagen (QGEN), Repligen (RGEN), Adaptive Biotechnologies (ADPT), Novavax (NVAX), Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA) and Iovance Biotherapeutics (IOVA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Intellia Therapeutics (NTLA), Canopy Growth (CGC), Square (SQ), Vertex Pharmaceuticals (VRTX) and Intel (INTC).

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Crispr Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Carnegie Capital Asset Management LLC (0.15%), Ipswich Investment Management Co. Inc. (0.06%), Patriot Financial Group Insurance Agency LLC (0.03%) and Carroll Financial Associates Inc. (0.00%). Company insiders that own Crispr Therapeutics stock include Bradley J Phd Bolzon, Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Tony W Ho and Vertex Pharmaceuticals (Europe. View institutional ownership trends for Crispr Therapeutics.

CRSP stock was sold by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC, and Ipswich Investment Management Co. Inc.. Company insiders that have sold Crispr Therapeutics company stock in the last year include Bradley J Phd Bolzon, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, and Tony W Ho. View insider buying and selling activity for Crispr Therapeutics.

CRSP stock was bought by a variety of institutional investors in the last quarter, including Carnegie Capital Asset Management LLC, and Carroll Financial Associates Inc.. View insider buying and selling activity for Crispr Therapeutics.

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRSP stock can currently be purchased for approximately $89.47.

Crispr Therapeutics has a market capitalization of $5.54 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe.

The official website for Crispr Therapeutics is www.crisprtx.com.

Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]